Trial Profile
Comparison of DPP-4 inhibitor, sitagliptin and nateglinide, and liraglutide and exenatide in type 2 diabetes: a CGM based-study
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 08 Jun 2016
Price :
$35
*
At a glance
- Drugs Exenatide (Primary) ; Liraglutide (Primary) ; Nateglinide (Primary) ; Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 02 Jun 2016 Status changed from active, no longer recruiting to withdrawn prior to enrolment.
- 24 Apr 2014 Status changed from recruiting to active,no longer recruiting as reported by University Hospital Medical Information Network - Japan.
- 07 Jan 2012 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.